...
search icon
nvct-img

Nuvectis Pharma Inc Share Price

NVCT
NAQ
$8.63
-$0.29
(-3.25%)
1D
Industry: Biotechnology Sector: Health Care

Nuvectis Pharma Inc Analyst Forecast

Nuvectis Pharma Inc Share Price Chart

Nuvectis Pharma Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$236.31M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
35.69K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.30
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$5.55 L
$11.52 H
$8.63

About Nuvectis Pharma Inc, Common Stock

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. more

Industry: BiotechnologySector: Health Care

Nuvectis Pharma Inc Stock Returns

Time FrameNVCTSectorS&P500
1-Week Return-1.71%0.72%-1.31%
1-Month Return6.41%1.27%0.78%
3-Month Return42.64%3.13%3.46%
6-Month Return33.8%15.81%6.19%
1-Year Return11.5%8.89%11.68%
3-Year Return-14.55%20.79%71.21%
5-Year Return165.54%35.89%74.81%

Nuvectis Pharma Inc Financials

Dec '21Dec '22Dec '23Dec '24Dec '255YR TREND
Total Revenue-149.00K---[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Cost of Revenue12.89M19.23M22.90M--[{"date":"2021-12-31","value":56.31,"profit":true},{"date":"2022-12-31","value":84,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Gross Profit(12.89M)(19.09M)(22.90M)--[{"date":"2021-12-31","value":-1289400000,"profit":false},{"date":"2022-12-31","value":-1908500000,"profit":false},{"date":"2023-12-31","value":-2289700000,"profit":false},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Gross Margin-(12808.72%)---[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-12808.72,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Operating Expenses12.89M19.23M22.90M19.85M27.57M[{"date":"2021-12-31","value":46.76,"profit":true},{"date":"2022-12-31","value":69.75,"profit":true},{"date":"2023-12-31","value":83.04,"profit":true},{"date":"2024-12-31","value":71.98,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Operating Income(12.89M)(19.23M)(22.90M)(19.85M)(27.57M)[{"date":"2021-12-31","value":-1289400000,"profit":false},{"date":"2022-12-31","value":-1923400000,"profit":false},{"date":"2023-12-31","value":-2289700000,"profit":false},{"date":"2024-12-31","value":-1984700000,"profit":false},{"date":"2025-12-31","value":-2757400000,"profit":false}]
Total Non-Operating Income/Expense8.00K298.00K1.11M1.69M2.26M[{"date":"2021-12-31","value":0.35,"profit":true},{"date":"2022-12-31","value":13.16,"profit":true},{"date":"2023-12-31","value":49.12,"profit":true},{"date":"2024-12-31","value":74.82,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Pre-Tax Income(12.89M)(19.09M)(22.26M)(19.00M)(26.44M)[{"date":"2021-12-31","value":-1289000000,"profit":false},{"date":"2022-12-31","value":-1908500000,"profit":false},{"date":"2023-12-31","value":-2226000000,"profit":false},{"date":"2024-12-31","value":-1900000000,"profit":false},{"date":"2025-12-31","value":-2644200000,"profit":false}]
Income Taxes(4.00K)(298.00K)1.00K(19.00M)-[{"date":"2021-12-31","value":-400,"profit":false},{"date":"2022-12-31","value":-29800,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-1900000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}]
Income After Taxes(12.89M)(18.79M)(22.26M)--[{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Income From Continuous Operations(12.89M)(19.23M)(22.33M)(19.00M)(26.44M)[{"date":"2021-12-31","value":-1289000000,"profit":false},{"date":"2022-12-31","value":-1923400000,"profit":false},{"date":"2023-12-31","value":-2233400000,"profit":false},{"date":"2024-12-31","value":-1900000000,"profit":false},{"date":"2025-12-31","value":-2644200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Net Income(12.89M)(18.79M)(22.26M)(19.00M)(26.44M)[{"date":"2021-12-31","value":-1288600000,"profit":false},{"date":"2022-12-31","value":-1878700000,"profit":false},{"date":"2023-12-31","value":-2226000000,"profit":false},{"date":"2024-12-31","value":-1900000000,"profit":false},{"date":"2025-12-31","value":-2644200000,"profit":false}]
EPS (Diluted)(24.91)(1.51)(1.43)(1.10)(1.32)[{"date":"2021-12-31","value":-2491,"profit":false},{"date":"2022-12-31","value":-151,"profit":false},{"date":"2023-12-31","value":-143,"profit":false},{"date":"2024-12-31","value":-110.2,"profit":false},{"date":"2025-12-31","value":-132,"profit":false}]

Nuvectis Pharma Inc Ratios

Nuvectis Pharma Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

NVCT
Current Ratio 2.38

Nuvectis Pharma Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NVCT
ROA (LTM) -68.50%
ROE (LTM) -188.03%

Nuvectis Pharma Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NVCT
Debt Ratio Lower is generally better. Negative is bad. 0.42
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.58

Nuvectis Pharma Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NVCT
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 12.62
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Nuvectis Pharma Inc share price today?

Nuvectis Pharma Inc (NVCT) share price today is $8.63

Can Indians buy Nuvectis Pharma Inc shares?

Yes, Indians can buy shares of Nuvectis Pharma Inc (NVCT) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NVCT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Nuvectis Pharma Inc be purchased?

Yes, you can purchase fractional shares of Nuvectis Pharma Inc (NVCT) via the Vested app. You can start investing in Nuvectis Pharma Inc (NVCT) with a minimum investment of $1.

How to invest in Nuvectis Pharma Inc shares from India?

You can invest in shares of Nuvectis Pharma Inc (NVCT) via Vested in three simple steps:

  • Click on Sign Up or Invest in NVCT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Nuvectis Pharma Inc shares
What is Nuvectis Pharma Inc 52-week high and low stock price?

The 52-week high price of Nuvectis Pharma Inc (NVCT) is $11.52. The 52-week low price of Nuvectis Pharma Inc (NVCT) is $5.55.

What is Nuvectis Pharma Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Nuvectis Pharma Inc (NVCT) is

What is Nuvectis Pharma Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Nuvectis Pharma Inc (NVCT) is 12.62

What is Nuvectis Pharma Inc dividend yield?

The dividend yield of Nuvectis Pharma Inc (NVCT) is 0.00%

What is the Market Cap of Nuvectis Pharma Inc?

The market capitalization of Nuvectis Pharma Inc (NVCT) is $236.31M

What is Nuvectis Pharma Inc's stock symbol?

The stock symbol (or ticker) of Nuvectis Pharma Inc is NVCT

How Can Investors Use Nuvectis Pharma Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Nuvectis Pharma Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Nuvectis Pharma Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Nuvectis Pharma Inc shares for Indian investors?

When investing in Nuvectis Pharma Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Nuvectis Pharma Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Nuvectis Pharma Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Nuvectis Pharma Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Nuvectis Pharma Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top